^“The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction”. Hum. Mol. Genet.7 (8): 1277–84. (August 1998). doi:10.1093/hmg/7.8.1277. PMID9668170.
^“Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells”. J. Biol. Chem.273 (16): 10058–67. (April 1998). doi:10.1074/jbc.273.16.10058. PMID9545353.
^“Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140”. J. Biol. Chem.264 (14): 7768–71. (May 1989). doi:10.1016/S0021-9258(18)83104-0. PMID2470733.
^“Association between platelet activation and fibrinolysis in acute stroke patients”. Neurosci. Lett.384 (3): 305–9. (August 2005). doi:10.1016/j.neulet.2005.04.090. PMID15916851.
^“Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow”. Blood95 (10): 3146–52. (May 2000). doi:10.1182/blood.V95.10.3146. PMID10807781.
^“Comparison of human eosinophil and neutrophil ligands for P-selectin: ligands for P-selectin differ from those for E-selectin”. Am. J. Respir. Cell Mol. Biol.12 (3): 315–9. (March 1995). doi:10.1165/ajrcmb.12.3.7532979. PMID7532979.
^“P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis”. Arch. Immunol. Ther. Exp. (Warsz.)54 (2): 75–84. (2006). doi:10.1007/s00005-006-0010-6. PMID16648968.
^Gasic GJ (1984). “Role of plasma, platelets, and endothelial cells in tumor metastasis”. Cancer Metastasis Rev.3 (2): 99–114. doi:10.1007/BF00047657. PMID6386144.
^“Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines”. Int. J. Cancer120 (6): 1179–91. (March 2007). doi:10.1002/ijc.22424. PMID17154173.
^“P-selectin mediates metastatic progression through binding to sulfatides on tumor cells”. Glycobiology17 (2): 185–96. (February 2007). doi:10.1093/glycob/cwl059. PMID17043066.
^“Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species”. Blood70 (2): 551–7. (August 1987). doi:10.1182/blood.V70.2.551.551. PMID2955820.
^“The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials”. J. Thromb. Haemost.5 (4): 729–37. (April 2007). doi:10.1111/j.1538-7836.2007.02427.x. PMID17408406.
“Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans”. Semin. Thromb. Hemost.28 (1): 53–66. (2002). doi:10.1055/s-2002-20564. PMID11885026.
“Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation”. Trends in Molecular Medicine10 (4): 171–8. (2004). doi:10.1016/j.molmed.2004.02.008. PMID15059608.
“P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis”. Arch. Immunol. Ther. Exp. (Warsz.)54 (2): 75–84. (2006). doi:10.1007/s00005-006-0010-6. PMID16648968.